Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

4
71
2
3

Year Published

1983
1983
2011
2011

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 154 publications
(80 citation statements)
references
References 56 publications
4
71
2
3
Order By: Relevance
“…There are only minor differences in binding properties between human and rabbit CRP; both bind strongly to phosphocholine (12). In contrast, some of the C-reactive proteins described in other species are glycoproteins, some are hexamers, and most do not demonstrate marked acute phase reactivity (1,2).…”
Section: Introductionmentioning
confidence: 94%
See 1 more Smart Citation
“…There are only minor differences in binding properties between human and rabbit CRP; both bind strongly to phosphocholine (12). In contrast, some of the C-reactive proteins described in other species are glycoproteins, some are hexamers, and most do not demonstrate marked acute phase reactivity (1,2).…”
Section: Introductionmentioning
confidence: 94%
“…Although C-reactive protein (CRP)l has been detected in the plasma of many species (1,2), it has been shown to behave as a striking acute phase reactant in only man (3), monkey (4), and the rabbit (5). In man and rabbits, CRP concentration rises rapidly after tissue injury or infection (6,7) and the magnitude of the response is remarkable; concentrations as much as 1,000 or more times normal levels may be attained.…”
Section: Introductionmentioning
confidence: 99%
“…This is because, despite the considerable phylogenetic conservation of CRP structure, there are substantial differences between CRPs of different species with respect to the fine details of ligand recognition, secondary effects of ligand binding including complement activation, normal concentrations, and behavior as acute-phase reactants. 37,38 In regard to human intervention studies, randomized trials have shown that statins can lower CRP concentration in healthy participants and in people with stable vascular disease. 39 The Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER trial) showed that rosuvastatin reduced the risk of first-ever vascular disease in people who have lower than average LDL cholesterol concentration and higher than average CRP concentration.…”
Section: Article See P 2088mentioning
confidence: 99%
“…These artifactual heterologous systems may not provide physiologically relevant information. Despite the evolutionary conservation of sequence, subunit organization, and protein fold, there are considerable variations between CRPs of different species with respect to fine ligand-binding specificity, presence and nature of glycosylation, protomer assembly, capacity to precipitate and aggregate ligands, base-line circulating concentrations, behavior as acute-phase proteins, and capacity to activate autologous complement (7)(8)(9). Indeed, only human CRP has been rigorously shown to activate complement in isologous serum.…”
mentioning
confidence: 99%